Oh AS, et al. (2008) Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol 28, 6580-93 18765637

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y1357-p - SRC-3 (human) ▲

Modsite: HPQAASIyQSSEMKG SwissProt Entrez-Gene Orthologous residues SRC‑3 (human): Y1357‑p, SRC‑3 iso2 (human): Y1342‑p, SRC‑3 (mouse): Y1331‑p, SRC‑3 (rat): Y1015‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  breast cancer, lung cancer Relevant cell lines - cell types - tissues:  A549 (pulmonary), breast, CHO-K1 (fibroblast), COS (fibroblast), HEK293T (epithelial), HeLa (cervical), MCF-7 (breast cell), MDA-MB-231 (breast cell) Cellular systems studied:  cell lines, tissue Species studied:  green monkey, hamster, human, mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE Abl (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Abl (human) siRNA inhibition of enzyme, phospho-antibody, transfection of constitutively active enzyme, co-immunoprecipitation, pharmacological inhibitor of upstream enzyme, modification site within consensus motif, pharmacological activator of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IGF-1 increase EGF increase estradiol increase imatinib decrease Downstream Regulation Effect of modification (function):  molecular association, regulation Effect of modification (process):  cell growth, altered, transcription, altered Modification regulates interactions with:  Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays p300 (human) Induces co-immunoprecipitation CARM1 (human) Induces co-immunoprecipitation ER-alpha (human) Induces co-immunoprecipitation

Y1331-p - SRC-3 (mouse) ▲

Modsite: HPQPTPMyQPsDMKG SwissProt Entrez-Gene Orthologous residues SRC‑3 (human): Y1357‑p, SRC‑3 iso2 (human): Y1342‑p, SRC‑3 (mouse): Y1331‑p, SRC‑3 (rat): Y1015‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting Disease tissue studied:  breast cancer, lung cancer Relevant cell lines - cell types - tissues:  A549 (pulmonary), breast, CHO-K1 (fibroblast), COS (fibroblast), HEK293T (epithelial), HeLa (cervical), MCF-7 (breast cell), MDA-MB-231 (breast cell) Cellular systems studied:  cell lines, tissue Species studied:  green monkey, hamster, human, mouse Associated Diseases Diseases Alterations Comments breast cancer increased